Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia

被引：27

作者：

Yoest, Jennifer M. ^{[1
]}

Shirai, Cara Lunn ^{[2
]}

Duncavage, Eric J. ^{[2
]}

机构：

[1] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA

[2] Washington Univ, Dept Pathol & Immunol, St Louis, MO 63110 USA

来源：

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2020年 / 8卷

关键词：

measurable (minimal) residual disease; acute myeloid leukemia; next generation sequencing; unique molecular identifier; error-corrected sequencing; clinical applications of NGS; AML MRD; QUANTITATIVE RT-PCR; CLONAL HEMATOPOIESIS; TANDEM DUPLICATION; INDUCTION THERAPY; RARE MUTATIONS; DIGITAL PCR; RISK; AML; DIAGNOSIS; TRANSPLANTATION;

D O I：

10.3389/fcell.2020.00249

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Next generation sequencing (NGS) methods have allowed for unprecedented genomic characterization of acute myeloid leukemia (AML) over the last several years. Further advances in NGS-based methods including error correction using unique molecular identifiers (UMIs) have more recently enabled the use of NGS-based measurable residual disease (MRD) detection. This review focuses on the use of NGS-based MRD detection in AML, including basic methodologies and clinical applications.

引用

页数：10

共 50 条

[21] Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
Marisa J. L. Aitken
Farhad Ravandi
Keyur P. Patel
Nicholas J. Short
Journal of Hematology & Oncology, 14
[22] Measurable Residual Disease in High-Risk Acute Myeloid Leukemia
Cluzeau, Thomas
Lemoli, Roberto M.
McCloskey, James
Cooper, Todd
CANCERS, 2022, 14 (05)
[23] Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
Aitken, Marisa J. L.
Ravandi, Farhad
Patel, Keyur P.
Short, Nicholas J.
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[24] Widespread use of measurable residual disease in acute myeloid leukemia practice
Epstein-Peterson, Zachary D.
Devlin, Sean M.
Stein, Eytan M.
Estey, Elihu
Tallman, Martin S.
LEUKEMIA RESEARCH, 2018, 67 : 92 - 98
[25] Delving the depths of measurable residual disease negativity in acute myeloid leukemia
Freeman, Sylvie D.
HAEMATOLOGICA, 2022, 107 (12) : 2776 - 2778
[26] The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia
Buccisano, Francesco
Hourigan, Christopher S.
Walter, Roland B.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (06) : 547 - 556
[27] The Prognostic Significance of Measurable (“Minimal”) Residual Disease in Acute Myeloid Leukemia
Francesco Buccisano
Christopher S. Hourigan
Roland B. Walter
Current Hematologic Malignancy Reports, 2017, 12 : 547 - 556
[28] Measurable residual disease in pediatric acute myeloid leukemia: a systematic review
Segerink, W. H.
de Haas, V
Kaspers, G. J. L.
EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (04) : 451 - 459
[29] Role of Measurable Residual Disease in Older Adult Acute Myeloid Leukemia
Li, Xueyao
Tong, Xiuzhen
CLINICAL INTERVENTIONS IN AGING, 2023, 18 : 921 - 931
[30] Widespread Use of Measurable Residual Disease in Acute Myeloid Leukemia Practice
Epstein-Peterson, Zachary D.
Devlin, Sean M.
Stein, Eytan M.
Estey, Elihu H.
Tallman, Martin S.
BLOOD, 2017, 130

← 1 2 3 4 5 →